OncoMatch

OncoMatch/Clinical Trials/NCT04741945

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

Is NCT04741945 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metformin for preleukemia.

Phase 2RecruitingKirsten GrønbækNCT04741945Data as of May 2026

Treatment: MetforminThis is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).

Check if I qualify

Extracted eligibility criteria

Disease stage

Required: Stage VERY LOW-RISK, LOW-RISK (IPSS-R)

very low- or low-risk disease (IPSS-R score ≤3) in addition to a bone marrow blast percentage <5

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: metformin

Any prior treatment with metformin

Cannot have received: immunosuppressive therapy

Exception: corticosteroids

immunosuppressive therapy (with the exception of corticosteroids) within the past year

Cannot have received: chemotherapy

chemotherapy within the past year

Cannot have received: granulocyte colony-stimulating factor

Treatment with granulocyte colony-stimulating factor within the past 30 days

Cannot have received: hypomethylating agents (azacitidine, decitabine)

Prior therapy with hypomethylating agents (i.e., azacitidine, decitabine)

Lab requirements

Blood counts

Peripheral blood cytopenia is defined as hemoglobin (hgb) <11.3 g/dL (7 mmol/L) in women and hgb <12.9 g/dL (8 mmol/L) in men, platelet count <150 x 10^9/L, or neutrophil count <1.8 x 10^9/L

Kidney function

eGFR <45 mL/min

Liver function

total serum bilirubin >1.5 × upper limit of the normal range (ULN), serum alanine transaminase >3 × ULN

Cardiac function

severe cardiac disease (NYHA class 3-4)

eGFR <45 mL/min; total serum bilirubin >1.5 × ULN, serum alanine transaminase >3 × ULN; severe cardiac disease (NYHA class 3-4); Peripheral blood cytopenia is defined as hemoglobin (hgb) <11.3 g/dL (7 mmol/L) in women and hgb <12.9 g/dL (8 mmol/L) in men, platelet count <150 x 10^9/L, or neutrophil count <1.8 x 10^9/L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify